Clinical trials
HER2 clinical trials
Below are recruiting her2 clinical trials, each written for real people, not researchers. We’re tracking 604 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04817540RecruitingPhase 2
Testing anti-HER2 treatment for HER2-enriched early breast cancer
This trial tests an anti-HER2 medicine in people whose breast cancer is classified as “HER2-enriched” using a special lab test (PAM50). It aims to see whether this treatment can help prevent or control cancer that cannot be fully removed by surgery.
SeoulAges 19 years+ - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06883487Recruiting
Exploring HER2 testing in high-grade ovarian cancer
This study looks at how to best detect the HER2 protein in high-grade serous ovarian cancer. The goal is to improve treatment choices for people with this type of cancer.
Guangzhou, GuangdongAges 18–75 - NCT06837792RecruitingPhase 2
T-DXd vs hormone therapy for HER2-low advanced breast cancer
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
SeoulAges 19 years+ - NCT06942234RecruitingPhase 1/Phase 2
Study of JSKN016 for advanced HER2-negative breast cancer
This trial tests a new combination drug (JSKN016) for people with HER2-negative breast cancer that has spread or cannot be removed. It is for those who have not yet had advanced-stage treatment (except hormone therapy) and may offer a new option.
ShanghaiAges 18–75 - NCT07358182Recruiting
Trastuzumab-rezetecan for breast cancer with HER2 protein
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
Guangzhou, GuangdongAges 18 years+ - NCT07340398RecruitingPhase 2
Testing new drug combos for HER2-positive breast cancer not responding to first therapy
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
HangzhouAges 18–75 - NCT07593976RecruitingPhase 2
New PET scan to predict breast cancer treatment response
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
RouenAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT04684459RecruitingEarly Phase 1
CAR-T therapy for tumors with HER2 and PD-L1 markers
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Chengdu, SichuanAges 18–75 - NCT05795101RecruitingPhase 2
TRUDI trial for inflammatory breast cancer with HER2/low markers
This Phase 2 trial tests two medicines—durvalumab and trastuzumab deruxtecan—to treat stage III inflammatory breast cancer. It may help by controlling cancer growth using treatments aimed at specific breast cancer markers (HER2 positive or “HER2-low”).
Boston, MassachusettsAges 18 years+ - NCT05838066RecruitingPhase 3
KN026 plus HB1801 for HER2-positive advanced breast cancer
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
Beijing, chaoyangAges 18 years+ - NCT06145308RecruitingPhase 2
Precision treatment for salivary gland cancer
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
Beijing, Beijing MunicipalityAges 18–100 - NCT06289517Recruiting
PET scan for cancers with high HER2 levels
This study is testing a new type of PET scan that uses a special molecule (68Ga-Her2-affibody) to find tumors that have high levels of HER2. It may help doctors better see where your cancer is and decide on the best treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06348134RecruitingPhase 2
Anti-HER2 Therapy Before and After Surgery for HER2-Positive Breast Cancer
This trial tests a targeted therapy (anti-HER2) given before and after surgery for Nigerian women with HER2-positive breast cancer. It aims to see if this treatment helps shrink tumors and improve outcomes.
Ikeja, LagosAges 18 years+ - NCT06450314RecruitingPhase 2
De-escalating treatment for advanced HER2-positive breast cancer
This trial tests whether it's safe to reduce or stop some cancer treatments for people whose advanced HER2-positive breast cancer has been well-controlled for at least 2 years and has no detectable cancer cells in blood tests.
RennesAges 18 years+ - NCT06550063Recruiting
HER2 status in esophagogastric cancer and patient outcomes
This study looks back at medical records of people with a certain type of esophageal or stomach cancer to see how HER2 status relates to patient outcomes. It may help guide future treatment decisions.
Dublin, LeinsterAges Any age - NCT06774027Recruiting
Breast cancer antibody-drug conjugate treatment registry
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06949410RecruitingPhase 1
HER2 vaccine study for high-risk breast cancer
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
Indianapolis, IndianaAges 18 years+ - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+ - NCT07610720RecruitingPhase 2
Dalpiciclib With Anti-HER2 and Hormone Therapy for Advanced Breast Cancer
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Guangdong, GUANGZHOUAges 18–75 - NCT06764940RecruitingPhase 2
Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Duarte, CaliforniaAges 18 years+ - NCT06452277RecruitingPhase 3
Testing sevabertinib for advanced HER2-mutated lung cancer
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Newport Beach, CaliforniaAges 18 years+
Hear when a new HER2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2?
- Yes. Clin2 currently lists 604 recruiting her2 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.